11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022
The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc22-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc22-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Transient increases in urine albumin excretion are reported with short-term hyperglycemia, exercise, urine tract infections, sustained blood pressure elevation, heart failure, fever, and hyperlipidemia (451).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [451]
In the citing paper
“The ADA/ EASD statement recommends that patients with T2D who have established ASCVD, CKD, or clinical heart failure be treated with an SGLT2i (or GLP-1 RA) with proven cardiovascular bene fi t as part of a glucose-lowering regimen independent of HbA1c, but with consideration of patient-speci fi c factors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [145]
In the citing paper
“Both the ADA and KDIGO recommend annual screening of patients with diabetes for CKD (17,18) (Fig. 1).”
In the citing paper
“This recommendation is based on strong evidence that SGLT2i reduce CKD progression, HF, and ASCVD risk in patients with T2D and CKD.”
In the citing paper
“These trials enrolled participants with albuminuria (ACR ≥300 mg/g and ≥200 mg/g, respectively); therefore, current evidence is strongest in this population, as emphasized by ADA recommendations (17) (Table 1).”
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023 · cited 1×
“Intensive glycemic control with the goal of achieving near-normoglycemia has been shown in large prospective randomized studies to delay the onset and progression of albuminuria and reduced eGFR in patients with type 1 diabetes (50,51) and type 2 diabetes (1,52 – 57).”
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Cited by
Items 101–200 of 349
Wish, J. B., & Pérgola, P. E. (2022) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2022.09.002 · Cited by 24
Schechter, M., Cohen, C. M., Fishkin, A., Rozenberg, A., Yanuv, I., Sehtman-Shachar, D. R., Chodick, G., Clark, A., Abrahamsen, T. J., Lawson, J., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01829-0 · Cited by 24
Novel Markers in Diabetic Kidney Disease—Current State and Perspectives
Piwkowska, A., Zdrojewski, Ł., Heleniak, Z., & Dębska-Ślizień, A. M. (2022) · Diagnostics · doi:10.3390/diagnostics12051205 · Cited by 27
Ding, X., Wang, X., Du, J., Han, Q., Zhang, D., & Zhu, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.866252 · Cited by 19
“Selection criteria The following inclusion criteria were used: (1): Patients who are diagnosed as DN based on the presence of albuminuria and/or a reduced estimated glomerular filtration rate (eGFR) without signs or symptoms of other primary causes of renal damage, or based on pathological diagnosis (2);: Studies eval…”
BackgroundMethodKurtzhals, P., Kreiner, F. F., & Bindra, R. S. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110881 · Cited by 22
Ding, X., Zhang, D., Ren, Q., Hu, Y., Wang, J., Hao, J., Wang, H., Zhao, X., Wang, X., Song, C., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713560 · Cited by 20
Chen, X., Qin, Y., Hu, J., Shen, Y., Mao, Y. J., Xie, L., Li, J., Wang, J., Yang, S., Li, Q., et al. (2024) · Diabetes & Metabolism · doi:10.1016/j.diabet.2024.101583 · Cited by 20
Dapagliflozin for the treatment of chronic kidney disease
Kurata, Y., & Nangaku, M. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2099373 · Cited by 21
Curovic, V. R., Eickhoff, M. K., Rönkkö, T., Frimodt‐Møller, M., Hansen, T. W., Mischak, H., Rossing, P. R., Ahluwalia, T. S., & Persson, F. (2022) · Diabetes Care · doi:10.2337/dc22-1157 · Cited by 20
Jabbour, S. A., Ibrahim, N. E., & Argyropoulos, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11206051 · Cited by 20
Yadegar, A., Mohammadi, F., Rabizadeh, S., Ayati, A., Seyedi, S. A., Nabipoorashrafi, S. A., Esteghamati, A., & Nakhjavani, M. (2023) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24954 · Cited by 21
Yang, Q., Yang, W., & Liu, F. (2023) · International Urology and Nephrology · doi:10.1007/s11255-023-03863-z · Cited by 18
Cherney, D. Z. I., Bell, A., Girard, L., McFarlane, P. A., MOIST, L. M., Nessim, S. J., Soroka, S. D., Stafford, S. G., Steele, A., Tangri, N., et al. (2023) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581221150556 · Cited by 22
McGill, J. B., Agarwal, R., Anker, S. D., Bakris, G. L., Filippatos, G. S., Pitt, B., Ruilope, L. M., Birkenfeld, A. L., Caramori, M. L., BRINKER, M. D., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14999 · Cited by 20
Bell, D. S. H., McGill, J. B., & Jerkins, T. W. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15181 · Cited by 19
Berhe, K. K., Mselle, L. T., & Gebru, H. B. (2023) · PLoS ONE · doi:10.1371/journal.pone.0290240 · Cited by 17
Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease
Wu, Y., Lin, H., Tao, Y., Xu, Y., Chen, J., Jia, Y., & Zheng, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.967317 · Cited by 19
“Mineralocorticoid receptor antagonist (MRA) has been proven to effectively protect the cardiovascular system and the kidney by competitively combining with MR (Draznin et al., 2022).”
BackgroundInfluentialZhang, Q., Xiao, S., Zou, F., Jiao, X., & Shen, Y. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101616 · Cited by 16
Blazek, O., & Bakris, G. L. (2022) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2022.100187 · Cited by 20
“…from essentially no therapy other than glycemic control to slow kidney disease in the late 1970s to now three distinctly different classes of drugs with a strong evidence base and level A recommendations in the guidelines (American Diabetes Association Professional Practice C et al., 2022) [1].”
BackgroundFinerenone: towards a holistic therapeutic approach to patients with diabetic kidney disease
Górriz, J. L., González‐Juanatey, J. R., Fácila, L., Soler, M. J., Valle, A., & Ortíz, A. (2023) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2023.09.002 · Cited by 18
Barrera‐Chimal, J., Gerarduzzi, C., Rossignol, P., & Jaisser, F. (2022) · Clinical Science · doi:10.1042/cs20220212 · Cited by 19
Pochopień, M., Cherney, D. Z. I., Drzewiecka, A., Folkerts, K., Levy, P., Millier, A., Morris, S., Palarczyk, M., Roy-Chaudhury, P., Sullivan, S. D., et al. (2022) · The American Journal of Managed Care · doi:10.37765/ajmc.2022.89212 · Cited by 16
Surawatsatien, N., Pongsachareonnont, P., Kulvichit, K., Varadisai, A., Somkijrungroj, T., Mavichak, A., Kongwattananon, W., Suwajanakorn, D., Phasukkijwatana, N., & Srisawat, N. (2023) · Translational Vision Science & Technology · doi:10.1167/tvst.12.4.19 · Cited by 15
Barr, S. I., Bessa, S. S. E.-D., Mohamed, T. M., & El-Azeem, E. M. A. (2024) · Diabetology International · doi:10.1007/s13340-023-00686-2 · Cited by 16
“…into three groups based on criteria that were set by the American Diabetes Association according to the albumin-to-creatinine ratio (ACR) [20], normoalbumi-nuria ( n = 25, ACR 30 mg/g creatinine) (GR II), microal-buminuria ( n = 25, ACR 30–300 mg/g creatinine) (GR III), and…”
Zhang, F., Han, Y., Zheng, G., & Li, W. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s451628 · Cited by 21
“51 Previous studies have debated gender differences in renal dysfunction, with some reporting a greater predisposition for renal dysfunction in male patients with T2DM, 37,52 and others suggesting a greater predisposition for renal dysfunction in female patients.”
BackgroundMitochondrial RNAs as Potential Biomarkers of Functional Impairment in Diabetic Kidney Disease
Mauro, S. D., Scamporrino, A., Filippello, A., Marco, M. D., Martino, M. T. D., Scionti, F., Pino, A. D., Scicali, R., Malaguarnera, R., Purrello, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158198 · Cited by 15
Li, X., Wu, H., Peng, H., & Jiang, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1078686 · Cited by 16
Eliasson, B., Lyngfelt, L., Strömblad, S.-O., Franzén, S., & Eeg‐Olofsson, K. (2022) · Scientific Reports · doi:10.1038/s41598-022-22932-4 · Cited by 20
Kwiendacz, H., Wijata, A. M., Nalepa, J., Piaśnik, J., Kulpa, J., Herba, M., Boczek, S., Kegler, K., Hendel, M., Irlik, K., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01938-w · Cited by 18
Validation of the Klinrisk chronic kidney disease progression model in the FIDELITY population
Tangri, N., Ferguson, T. W., Leon, S. J., Anker, S. D., Filippatos, G. S., Pitt, B., Rossing, P. R., Ruilope, L. M., Farjat, A. E., Farag, Y. M. K., et al. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae052 · Cited by 14
“Clinical practice guidelines recommend kidney function should be regularly monitored in patients with diabetes, and early detection and risk stratification are prioritized to ensure early diagnosis and treatment [4 –6 ].”
BackgroundTiwari, D., & Aw, T. C. (2024) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2024.00013 · Cited by 19
Control of Mitochondrial Quality: A Promising Target for Diabetic Kidney Disease Treatment
Li, Q., Shang, J., & Inagi, R. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.12.029 · Cited by 17
Groehl, F., Garreta-Rufas, A., Meredith, K., Harris, J. E., Rossing, P. R., Hobbs, R. F., & Wanner, C. (2023) · Clinical Nephrology · doi:10.5414/cn111106 · Cited by 13
Framework of Guidelines for Management of CKD in Asia
Pollock, C. A., Moon, J., Ha, L. P. N., Gojaseni, P., Ching, C. H., Gomez, L., Chan, T. M., Wu, M., Yeo, S. C., Nugroho, P., et al. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.12.010 · Cited by 15
Tiwari, D., Loh, W. J., & Aw, T. C. (2025) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2025.101428 · Cited by 17
Ooi, S.-W., Yeh, S., Chang, Y., Li, C., & Chen, H.-F. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272137 · Cited by 15
Doi, Y., Hamano, T., Yamaguchi, S., Sakaguchi, Y., Kaimori, J., & Isaka, Y. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15191 · Cited by 13
Albarrán, O. G., Morales, C., Pérez-Maraver, M., Aparicio-Sánchez, J. J., & Simó, R. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01276-2 · Cited by 16
Raimundo, J. R. S., Alves, B. D. C. A., Encinas, J. F. A., Siqueira, A. M., de Gois, K. C., Perez, M. M., Petri, G., dos Santos, J. F. R., Fonseca, F. L. A., & da Veiga, G. L. (2023) · Scientific Reports · doi:10.1038/s41598-023-41061-0 · Cited by 12
“DN is the main cause of chronic kidney disease (CKD) in patients referred for hemodialysis 13 ; therefore, monitoring of the glomerular filtration rate (GFR) through creatinine clearance and microalbuminuria after the diagnosis of DM is recommended 14 .”
Wang, Y., & Xia, N. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1897-6121 · Cited by 13
Llauradó, G., Vlacho, B., Wargny, M., Ruan, Y., Franch‐Nadal, J., Domingo, P., Gourdy, P., Saulnier, P., Hadjadj, S., Wild, S. H., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01657-8 · Cited by 13
Chronic kidney disease in patients with type 2 diabetes: new targets of medicine action
Trubitsyna, N. P., Zaytseva, N. V., Severina, A. S., & Шамхалова, М. Ш. (2022) · Diabetes Mellitus · doi:10.14341/dm12944 · Cited by 13
Novel Biomarkers for the diagnosis of diabetic nephropathy.
Concepción‐Zavaleta, M. J., Quiroz, J., Suárez-Rojas, J., Paz, J., Roseboom, P. J., Ildefonso-Najarro, S. P., Cribilleros, D., Zavaleta‐Gutiérrez, F. E., Coronado, J., & Concepción, L. (2024) · PubMed Central · doi:10.22088/cjim.15.3.382 · Cited by 17
“This occurs in 20-40% of patients with DM (7).”
BackgroundYang, W., Zhong, Y., Zhou, P., & Lu, D. (2025) · Renal Failure · doi:10.1080/0886022x.2024.2438846 · Cited by 11
“Last, because a diagnosis of DKD can be made in clinical practice based on albuminuria or eGFR in the absence of other kidney damage, the patients included in our study were diagnosed with DKD without kidney biopsy [23].”
Bao, W., Zhang, M., Li, N., Yao, Z., & Sun, L. (2022) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-022-03408-w · Cited by 13
Effects of Mediterranean diets and nutrigenomics on cardiovascular health
Bakrim, S., Aboulaghras, S., Aanniz, T., Benali, T., Omari, N. E., El‐Shazly, M., Lee, L., Mustafa, S. K., Sahib, N., Ребезов, М. Б., et al. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2023.2187622 · Cited by 15
Albuminuria Screening in People With Type 2 Diabetes in a Managed Care Organization
Keong, F., Gander, J. C., Wilson, D. J., Durthaler, J. M., Pimentel, B., & Barzilay, J. I. (2023) · AJPM Focus · doi:10.1016/j.focus.2023.100133 · Cited by 13
Hagiwara, S., Gohda, T., Kantharidis, P., Okabe, J., Murakoshi, M., & Suzuki, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020869 · Cited by 11
“Moreover, the recently published annual guidelines from the American Diabetes Association, Standards of Medical Care in Diabetes , recommend the use of finerenone to slow the progression of CKD and reduce cardiovascular events [23].”
BackgroundHosojima, M., Kabasawa, H., Kaseda, R., Ishikawa-Tanaka, T., Obi, Y., Murayama, T., Kuwahara, S., Suzuki, Y., Narita, I., & Saito, A. (2022) · Kidney360 · doi:10.34067/kid.0002982022 · Cited by 11
Zhang, Y., Wang, J., Jiang, L., Wang, T., Li, Z., Fu, X., Huang, W., Xiao, Y., Wang, S., & Zhao, J. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00929-3 · Cited by 11
“American Diabetes Association (ADA) suggested that in patients with T2DM and CKD who were at increased risk for cardiovascular events or CKD progression or are unable to use a SGLT2i, finerenone was recommended to reduce CKD progression and cardiovascular events [12].”
BackgroundA cohort study found a high risk of end-stage kidney disease associated with acromegaly
Hong, S., Kim, K., Han, K., & Park, C. (2023) · Kidney International · doi:10.1016/j.kint.2023.06.037 · Cited by 11
Causal effect of gut microbiota and diabetic nephropathy: a Mendelian randomization study
He, G., Chen, J., Hao, W., & Hu, W. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01327-7 · Cited by 10
Knowler, W. C., Chen, H., Bahnson, J. L., Kahn, S. E., Lewis, C. E., Nathan, D. M., Nelson, R. G., Pilla, S. J., & Bantle, J. P. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004079 · Cited by 13
A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKD
Singh, A. K., Anker, S. D., Pitt, B., Rossing, P. R., Ruilope, L. M., Ahlers, C., Farag, Y. M. K., Lambelet, M., BRINKER, M. D., Rohwedder, K., et al. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.10.032 · Cited by 15
Liu, G., Zhong, X., Zheng, J., Zhang, J., Kong, W., Hu, X. F., Min, J., Xia, W., Zeng, T., & Chen, L. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01391-8 · Cited by 13
He, J., Song, C., Wang, H., Zhang, R., Yuan, S., & Dou, K. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110693 · Cited by 10
An Update on Semaglutide Research: A Bibliometric Analysis and a Literature Review
Dagli, N., Kumar, S., Ahmad, R., Narwaria, M., & Haque, M. (2023) · Cureus · doi:10.7759/cureus.46510 · Cited by 16
Ming, J., Hong, G., Xu, Y., Mernagh, P., Pochopień, M., & Li, H. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02906-w · Cited by 11
“Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) have long been first-line agents in the current standard of care (SoC) for patients with CKD and T2D [6, 7].”
Yang, Q., Zou, Y., Lang, Y., Yang, J., Wu, Y., Xiao, X., Qin, C., Zhao, Y., & Liu, F. (2024) · Renal Failure · doi:10.1080/0886022x.2024.2369701 · Cited by 11
“This situation leads to an increase in the prevalence of chronic kidney disease (CKD) attributed to DM (i.e., diabetic kidney disease, DKD) [2].”
BackgroundWang, J., Yang, J., Jiang, W., Liu, W., Shen, Z., Gao, Z., & Chang, B. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15860 · Cited by 10
Finerenona: completando el abordaje del paciente con enfermedad renal y diabetes
Górriz, J. L., González‐Juanatey, J. R., Fácila, L., Soler, M. J., Valle, A., & Ortíz, A. (2022) · Nefrología · doi:10.1016/j.nefro.2022.09.002 · Cited by 14
Liraglutide ameliorates diabetic kidney disease by modulating gut microbiota and L-5-Oxoproline
Yi, B., Su, K., Cai, Y., Chen, X., Bao, Y., & Wen, Z. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176905 · Cited by 12
van Mil, D., Kieneker, L. M., Harms, E., Prins, G. H., van Geer-Postmus, I., Mepschen, M., Leving, M. T., Stoker, N., Kocks, J. W. H., Gansevoort, R. T., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103185 · Cited by 10
Li, F., Han, J., Zhang, W., Lv, J., Wang, Z., Li, H., Jin, L., Feng, J., Lu, W., & Sun, J. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2545939 · Cited by 9
“Consequently, the american diabetes association (ada) recommends finerenone to slow CKd progression [22], and the 2022 Kidney disease: improving Global Outcomes (KdiGO) Clinical Practice Guideline endorses its use in t2d patients with persistent albuminuria despite receiving the maximum tolerated…”
Effect of once-weekly dulaglutide on renal function in patients with chronic kidney disease
Kim, S., An, J. N., Song, Y. R., Kim, S. G., Lee, H., Cho, A., & Kim, J.-K. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273004 · Cited by 10
Rossing, P. R., Groehl, F., Mernagh, P., Folkerts, K., Garreta-Rufas, A., Harris, J., Meredith, K., Carter, M., Åkerborg, Ö., Wanner, C., et al. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2235922 · Cited by 11
“%) is representative of the potential treatment effects for emerging therapies such as SGLT2is and/or finerenone, and is only applied to KDIGO categories G1-3b:A3 (as recommended by current guidelines) 19 .”
BackgroundMethodInfluentialXu, M., Feng, R., Feng, R., Yin, X., Zhang, L., Wang, C., & Liu, J. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003402 · Cited by 11
Hassanein, M. M., Sabbour, H. M., Alawadi, F., Abusnana, S., Afandi, B. O., Kaabi, J. A., Bashier, A. M., Cosentino, F., Tamimi, H. E., Farghali, M., et al. (2023) · Dubai Diabetes and Endocrinology Journal · doi:10.1159/000531107 · Cited by 9
“The clinical importance of screening and treating patients with diabetes and CKD/DKD to preserve kidney function and reduce CV risk is highlighted [59].”
Nicholas, S. B., Wright, E. E., Billings, L. K., Ambriz, E., Gee, P. O., & Peeler, T. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02325-9 · Cited by 10
Hegde, N. C., Kumar, A., Patil, A., Bhattacharjee, S., Gamad, N., Kasudhan, K. S., Kumar, V., & Rastogi, A. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02126-8 · Cited by 9
Economic evaluation of bailing capsules for patients with diabetic nephropathy in China
He, Y., Li, W., Zhu, H., & Han, S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1175310 · Cited by 9
Chai่jaroenkul, W., Youngvises, N., Thiengsusuk, A., Plengsuriyakarn, T., Suwanboriboon, J., Sirisabhabhorn, K., Meesiri, W., & Na‐Bangchang, K. (2025) · Biosensors · doi:10.3390/bios15060391 · Cited by 9
“By identifying microalbumin in urine, clinicians can assess the risk of chronic kidney disease (CKD), diabetic nephropathy, hypertension-related kidney damage, cardiovascular diseases, obesity-associated kidney dysfunction, and autoimmune kidney disorders [1–5].”
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2022) · Diabetologie und Stoffwechsel · doi:10.1055/a-1789-5650 · Cited by 10
Sundqvist, H., Heikkala, E., Jokelainen, J. J., Russo, G. T., Mikkola, I., & Hagnäs, M. P. (2022) · BMC Nephrology · doi:10.1186/s12882-022-02979-1 · Cited by 10
Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective
de Pouvourville, G., Rossignol, P., Boussahoua, M., Chevalier, J., Gabb, P. D., Poulnais, R., Verboux, D., Rao, N., Sörstadius, E., & Sánchez, J. J. G. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02574-2 · Cited by 10
“The latest American Diabetes Association 2022 guidelines included a grade A recommendation to use gliflozins for patients with T2D and diabetic kidney disease with an eGFR C 25 mL/min per 1.73 m 2 and UACR C 300 mg/g, to reduce CKD progression and cardiovascular events [22].”
InfluentialTateyama, Y., Shimamoto, T., Uematsu, M. K., Taniguchi, S., Nishioka, N., Yamamoto, K., Okada, H., Takahashi, Y., Nakayama, T., & Iwami, T. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1195167 · Cited by 10
Renoprotective Effects of Mineralocorticoid Receptor Antagonists Against Diabetic Kidney Disease
Bayne, S., LeFevre, J., Olstinske, K., Ravindran, S., & Munusamy, S. (2023) · Advanced Biology · doi:10.1002/adbi.202300496 · Cited by 9
Kolivas, D., Fraser, L., Schweitzer, R., Brukner, P. D., & Moschonis, G. (2025) · Nutrients · doi:10.3390/nu17060937 · Cited by 10
“The clinical diagnosis of diabetes-related CKD is characterised by a decrease in kidney function over time, as measured by the estimated glomerular filtration rate (eGFR) in the presence of longstanding T2D [7].”
Kourtidou, C., Rafailidis, V. D., Varouktsi, G., Kanakis, E., Liakopoulos, V., Vyzantiadis, T., Stangou, M. J., Marinaki, S., & Τζιόμαλος, Κ. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12071139 · Cited by 8
“Even though patients with DKD are considered to be already at very high cardiovascular risk and guidelines recommend aggressive medical treatment with high-dose, high-intensity statins and aspirin [41], the identification of subclinical vascular disease in this population might have implications for their management.”
BackgroundWilliamson, T. E., Gomez-Espinosa, E., Stewart, F., Dean, B. B., Singh, R., Cui, J., & Kong, S. X. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108548 · Cited by 8
Berry, S., Chubb, B., Acs, A., Falla, E., Verma, A., Malkin, S. J. P., Hunt, B., & Palmer, A. J. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2240957 · Cited by 7
“This approach was used recently in an economic evaluation conducted by NICE, which modelled a conventional care arm based on conventional risk factors using the UKPDS Outcomes Model 2 and then applied hazard ratios for myocardial infarction, stroke, ischaemic heart disease, and heart failure to model glucagon-like pep…”
MethodInfluentialCheng, Y.-C., Lu, C., Hsu, C., Sheu, M., & Lee, I. (2024) · Scientific Reports · doi:10.1038/s41598-024-61395-7 · Cited by 7
“Treatment with RAS blockade and SGLT2 inhibitors results in renal protection and mortality prevention, and these treatments are recommended for patients with increased UACR 46–50 .”
BackgroundMatsuda, T., Osaki, Y., Maruo, K., Matsuda, E., Suzuki, Y., Suzuki, H., Mathis, B. J., Shimano, H., & Mizutani, M. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03699-4 · Cited by 7
SGLT2 Inhibitors and Finerenone: A friendly Duo in the Treatment of Diabetic Kidney Disease?
Asirvatham, A. R., Asirvatham, A. J., & Mahadevan, S. (2024) · Journal of the Association of Physicians of India · doi:10.59556/japi.72.0759 · Cited by 7
NUAK1 Promotes Diabetic Kidney Disease by Accelerating Renal Tubular Senescence via the ROS/P53 Axis
Guo, L., Wu, P., Li, Q., Feng, Q., Lin, X., Luo, Y., Wang, Y., Wu, M., Cai, F., Zhang, J., et al. (2025) · Diabetes · doi:10.2337/db25-0417 · Cited by 12
Nikitin, D., Lin, G. A., Campbell, J. D., Hansen, R. N., Brouwer, E., Chen, Y., Herron-Smith, S., Agboola, F. O., & Pearson, S. D. (2022) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2022.28.6.680 · Cited by 9
Jiang, S., Zhang, D., & Li, W. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.952899 · Cited by 7
Nwosu, U. A., Darbinian, J. A., Chen, K. K., Zeng, B., Arzumanyan, H., Lo, J. C.-M., & Zheng, S. (2023) · Diabetes Care · doi:10.2337/dc22-1871 · Cited by 7
AT1 receptor downregulation: A mechanism for improving glucose homeostasis
Lopez, D. L., Casillas, O. E., Jaramillo, H. J., Romero‐García, T., & Vázquez-Jiménez, J. G. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i3.170 · Cited by 8
Klein, G., Petrone, M., Yang, Y., Hoang, T., Hazlett, S., Hansen, L. B., & Flor, A. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01239-1 · Cited by 7
Mentz, R. J., Anker, S. D., Pitt, B., Rossing, P. R., Ruilope, L. M., Gebel, M., Kolkhof, P., Lawatscheck, R., Rohwedder, K., & Bakris, G. L. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3569 · Cited by 11
GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2022) · Kidney and Dialysis · doi:10.3390/kidneydial2030034 · Cited by 7
Betts, K. A. (2022) · The American Journal of Managed Care · doi:10.37765/ajmc.2022.89211 · Cited by 10
Combination therapy with an SGLT ‐2 inhibitor and finerenone in DKD : Are we there yet?
Georgianos, P. I., Eleftheriadis, T., & Liakopoulos, V. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13864 · Cited by 8
Zhang, T., Wang, X., Zhang, Y., Yang, Y., Yang, C., Wei, H., & Zhao, Q. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04245-w · Cited by 7
Goh, Y. A., Lan, N. S. R., Linn, K., Wood, C., Gupta, A., Yeap, B. B., & Fegan, P. G. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108557 · Cited by 8
Zhang, Y., Jiang, L., Wang, J., Wang, T., Chien, C., Huang, W., Fu, X., Xiao, Y., Fu, Q., Wang, S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1623050/v1 · Cited by 7
Construction of a PANoptosis-Related Gene Signature for Diabetic Nephropathy
Li, G., Liu, Y., Sun, Y., & Chen, Y. (2025) · Kidney & Blood Pressure Research · doi:10.1159/000546764 · Cited by 6
“DKD was diagnosed based on American Diabetes Association standards, defined by at least two urine samples showing albumin excretion ≥ 30 mg/24 h or an albumin-to-creatinine ratio ≥ 30 mg/g [23].”
Lewellyan, C. M., Spoutz, P. M., Schaefer, M. G., & Patterson, M. E. (2022) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5496 · Cited by 7
Kjaergaard, A. D., Krakauer, J. C., Krakauer, N. Y., Teumer, A., Winkler, T. W., & Ellervik, C. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15037 · Cited by 6
Metadata
- Authors
- American Diabetes Association Professional Practice Committee
- Corresponding author
- American Diabetes Association Professional Practice Committee
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2021-12-16
- Volume
- 45
- Issue
- Supplement_1
- Pages
- S175-S184
- ISSN
- 0149-5992 (ISSN-L)
- OpenAlex
- W4200340161
- Semantic Scholar
- 40f2cfa2d0038ac9f80bb94b8f8217ad1566bd6e
- Cited by
- 344
- References
- 112
- Citations by year
- 2026: 15 · 2025: 38 · 2024: 66 · 2023: 123 · 2022: 101 · 2021: 1
- FWCI
- 11.91
- Type
- journal article
- Language
- en
- Update notices
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- chronic kidney disease, diabetes mellitus, risk management, clinical guidelines, quality of care
- MeSH terms
- Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Renal Insufficiency, Chronic, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.